The Changing Fortunes of Antibacterial Drug Development and Commercialisation
Add bookmark
The Changing Fortunes of Antibacterial Drug Development and Commercialisation
Add bookmark
The global market for anti-infective drugs is steadily growing and projected to increase by over 50% by the year 2015, to total US $100 billion. In this Pharma IQ interview Dr. Chris Thomson, Director of Licensing & Business Development at Astellas Pharma Europe, addresses the gap in antibacterial supply and demand. Thomson reflects on the changing dynamics of the antibacterial market and focuses on areas of unmet need.
[inlinead]
Tags:
anti-infectives
Chris Thomson
drug development
antibacterial
antibacterial supply and demand
antibacterial business
unmet need
